Answers are grounded in this paper and cite their sources.
The growth of the transgender and/or gender diverse (TGD) community has created an increased demand for comprehensive and evidence-based gender-affirming care, especially when providing a hormone-based regimen. Although there are known risks of adverse events from receiving exogenous hormone replacement therapy, many of these risks are typically attributed to members of the TGD community receiving estrogen-based therapy. In this report, a case of a subsegmental pulmonary embolism in a male patient assigned female at birth who was actively receiving testosterone-based, female-to-male gender-affirming care is detailed. In doing so, attention is drawn to a potential complication of this approach, thereby empowering clinicians and patients alike to be cognizant of such risks while still pursuing this otherwise pivotal and necessary care.
No takes yet. Share an insight, caveat, or question.
Thor et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: